Ebolavirus

European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older

Retrieved on: 
Thursday, September 7, 2023
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, MSD, Vaccination, Chills, Public, Anaphylaxis, Arthralgia, Rash, Committee, Milk, Plasma, Risk, Committee for Medicinal Products for Human Use, European, EVD, NYSE, Saliva, Fatigue, Disease, Antigen, Pregnancy, Diarrhea, Urine, Somnolence, MRK, Appetite, UNICEF, Merck & Co., Myalgia, Vomiting, Child, Immunodeficiency, Headache, Ebola, Irritability, Mouth, Safety, Screaming, Fever, Civil service commission, Arthritis, History, Abdominal pain, Hyperhidrosis, IG, Allergy, Dizziness, Blood, European Medicines Agency, European Commission, Breast milk, CHMP, Infection, European Directive on Traditional Herbal Medicinal Products, RNA, Nausea, EC, Vaccine, Birth control, Merck, EU, Ebolavirus, Marburgvirus

The vaccine was previously approved for use in the European Union (EU) for individuals 18 years of age or older.

Key Points: 
  • The vaccine was previously approved for use in the European Union (EU) for individuals 18 years of age or older.
  • “Ebola virus disease is severe and potentially life-threatening for both children and adults.
  • INDICATIONS AND USAGE IN THE U.S.
    ERVEBO® is indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older.
  • Effectiveness of the vaccine when administered concurrently with antiviral medication, immune globulin (IG), and/or blood or plasma transfusions is unknown.

U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older

Retrieved on: 
Thursday, August 3, 2023
Health, FDA, Infectious Diseases, Other Health, General Health, Pharmaceutical, Biotechnology, MSD, Vaccination, Marketing, Chills, Anaphylaxis, Arthralgia, Rash, Committee, Milk, Plasma, Risk, Committee for Medicinal Products for Human Use, European, EVD, NYSE, Saliva, Fatigue, Disease, Antigen, Pregnancy, Diarrhea, Urine, Somnolence, MRK, Appetite, UNICEF, Merck & Co., Myalgia, Vomiting, Child, Immunodeficiency, Headache, Irritability, Mouth, Safety, Screaming, Fever, Civil service commission, Arthritis, History, Abdominal pain, Hyperhidrosis, Ebola, IG, Allergy, Dizziness, Blood, European Medicines Agency, European Commission, Breast milk, CHMP, Infection, European Directive on Traditional Herbal Medicinal Products, RNA, Nausea, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Vaccine, Birth control, Merck, EU, Ebolavirus, Marburgvirus

The vaccine was previously approved for use in individuals 18 years of age and older.

Key Points: 
  • The vaccine was previously approved for use in individuals 18 years of age and older.
  • ERVEBO is currently authorized for use in the European Union (EU) for individuals 18 years of age and older.
  • ERVEBO® is indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older.
  • Effectiveness of the vaccine when administered concurrently with antiviral medication, immune globulin (IG), and/or blood or plasma transfusions is unknown.

KBI Biopharma Announces Subcontract with Mapp Biopharmaceutical on Sudan ebolavirus Treatment

Retrieved on: 
Monday, January 23, 2023
Research, Infectious Diseases, FDA, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Administration, MAPP, Human services, Office of Inspector General, U.S. Department of Health and Human Services, SUDV, Development, World Health Organization, Ebola, BARDA, Ebolavirus, KBI, Biomedical Advanced Research and Development Authority, Republic, Mapp Biopharmaceutical, Death, Administration for Strategic Preparedness and Response, Vaccine

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. (Mapp) for the continued development and manufacturing of MBP134, an experimental combination monoclonal antibody treatment for Sudan ebolavirus (SUDV)*.

Key Points: 
  • KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. (Mapp) for the continued development and manufacturing of MBP134, an experimental combination monoclonal antibody treatment for Sudan ebolavirus (SUDV)*.
  • KBI is playing an important role in supporting Mapp’s efforts by providing expedited product development support including analytical and manufacturing contributions across multiple global sites.
  • “SUDV is an urgent health crisis, and KBI is pleased to subcontract with Mapp, expediting the availability of MBP134 to make an impact,” said Dr. Abdelaziz Toumi, Chief Business Officer of KBI Biopharma and Selexis SA.
  • Currently, there is no cure for Sudan ebolavirus virus disease, which has a fatality rate of around 50%.

The Native Antigen Company Expands Infectious Disease Portfolio to Include Sudan Ebolavirus Boniface 1976 Glycoprotein

Retrieved on: 
Thursday, December 8, 2022
Medical Devices, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Antigen, Ebolavirus, SEBOV, Infection, HEK 293 cells, Research, Ebola, Disease, Antibody, Cell, Human, Vaccine, Immunoassay, Mortality, Health, EBOV, Sudan ebolavirus

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the worlds leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial release of its Sudan Ebolavirus Boniface 1976 Glycoprotein (SEBOV GP).

Key Points: 
  • The Native Antigen Company (part of LGC Clinical Diagnostics), one of the worlds leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial release of its Sudan Ebolavirus Boniface 1976 Glycoprotein (SEBOV GP).
  • Sudan Ebolavirus is a species of ebolavirus responsible for severe disease in humans, Ebola haemorrhagic fever, for which there are currently no licensed vaccines or treatments available.
  • The Native Antigen Companys SEBOV GP is designed for use in immunoassay and vaccine development to support research into the deadly disease.
  • For further information about The Native Antigen Companys Sudan Ebolavirus Boniface 1976 Glycoprotein, please visit: https://thenativeantigencompany.com/products/ebola-virus-envelope-glycop...

AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes

Retrieved on: 
Monday, November 28, 2022
Aikido, ASPI, University, University of Maryland, College Park, Pancreatic cancer, Biotechnology, Middle East respiratory syndrome–related coronavirus, IPO, University of Texas at Austin, Risk, Memory, Therapy, Prostate cancer, ASP, Coronavirus, Isotope, Security (finance), Ebolavirus

NEW YORK, Nov. 28, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today announced the successful initial public offering ("IPO") of ASP Isotopes ("ASPI"). ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses.

Key Points: 
  • Leading Advanced Materials Company Now Listed on NASDAQ under the symbol, ASPI
    NEW YORK, Nov. 28, 2022 /PRNewswire/ --AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today announced the successful initial public offering ("IPO") of ASP Isotopes ("ASPI").
  • ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses.
  • Mr. Anthony Hayes, CEO of AIkido stated, "As a shareholder of ASP Isotopes, we want to congratulate the company and their CEO, Paul Mann on successfully listing on NASDAQ.
  • We congratulate Paul and his team for getting this public offering over the line.

AIkido Share Repurchase Continues

Retrieved on: 
Thursday, October 6, 2022
Aikido, Pancreatic cancer, Therapy, Middle East respiratory syndrome–related coronavirus, SEC, Securities Exchange Act of 1934, Biotechnology, Special-purpose acquisition company, Program, University of Maryland, College Park, Coronavirus, Nasdaq, University, Company, Share repurchase, Board, Prostate cancer, Board of directors, University of Texas at Austin, Risk, Security (finance), Ebolavirus

NEW YORK, Oct. 6, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.

Key Points: 
  • NEW YORK, Oct. 6, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.
  • The Company reported that on October 5, 2022, the Company purchased 10,500 shares of common stock at $7.0679 per share.
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics.
  • Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws.

AIkido Purchases More Shares

Retrieved on: 
Wednesday, October 5, 2022
Aikido, Pancreatic cancer, Therapy, Middle East respiratory syndrome–related coronavirus, SEC, Securities Exchange Act of 1934, NASDAQ, Biotechnology, Special-purpose acquisition company, Program, University of Maryland, College Park, Coronavirus, University, Company, Share repurchase, Board, CEO, Prostate cancer, Board of directors, University of Texas at Austin, Risk, Security (finance), Ebolavirus

NEW YORK, Oct. 5, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.

Key Points: 
  • NEW YORK, Oct. 5, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.
  • The Company reported that on October 4, 2022, the Company purchased 38,035 shares of common stock at $6.99 per share.
  • Anthony Hayes, CEO of AIkido stated, "We believe the Company stock continues to be undervalued and we are using this opportunity to enhance shareholder value by reducing the amount of stock that is outstanding."
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics.

Share Repurchase Program Continues

Retrieved on: 
Tuesday, October 4, 2022
Securities Exchange Act of 1934, Genta (company), Aikido, SEC, University, Risk, Nasdaq, Middle East respiratory syndrome–related coronavirus, University of Texas at Austin, Share repurchase, Pancreatic cancer, Coronavirus, Program, Biotechnology, University of Maryland, College Park, Board of directors, Prostate cancer, Board, Therapy, Company, Security (finance), Ebolavirus

NEW YORK, Oct. 4, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.

Key Points: 
  • NEW YORK, Oct. 4, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.
  • The Company reported that on October 3, 2022, the Company purchased 45,000 shares of common stock at $6.98 per share.
  • The timing, number of shares repurchased, and prices paid for the stock under this program will depend on general business and market conditions as well as corporate and regulatory limitations, including blackout period restrictions.
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics.

AIkido Pharma Continues Share Repurchase Program

Retrieved on: 
Monday, October 3, 2022
Securities Exchange Act of 1934, Special-purpose acquisition company, Aikido, SEC, University, Risk, Nasdaq, CEO, Middle East respiratory syndrome–related coronavirus, University of Texas at Austin, Share repurchase, Pancreatic cancer, Coronavirus, Program, Biotechnology, University of Maryland, College Park, Board of directors, Prostate cancer, Board, Therapy, Company, Online gambling, Security (finance), Ebolavirus

NEW YORK, Oct. 3, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the $3 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.

Key Points: 
  • NEW YORK, Oct. 3, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the $3 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.
  • The Company reported that on September 30, 2022, the Company purchased 41,096 shares of common stock at $ 7.1034 per share.
  • Anthony Hayes, CEO of Aikido stated, "The Company's stock price is still below our book value, so we are continuing to allocate capital under our repurchase plan.
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics.

Dominari Financial, Inc. Executes Definitive Agreement to Buy Broker-Dealer

Retrieved on: 
Friday, September 9, 2022
University, NASDAQ, Biotechnology, Industry, Prostate cancer, Pancreatic cancer, FINRA, UHNW, Technology, Risk, Science and technology in Asia, SEC, Company, Therapy, Aikido, Intention, Coronavirus, Middle East respiratory syndrome–related coronavirus, Acquisition, Security (finance), Financial services, Ebolavirus

NEW YORK, Sept. 9, 2022 /PRNewswire/ -- Dominari Financial, Inc., the financial services subsidiary of AIkido Pharma Inc., (NASDAQ: AIKI) has entered into an exclusive agreement for the acquisition of a broker-dealer firm. This is Dominari's first acquisition since launching in June. Details of the proposed purchase can be found in the 8K on file with the SEC.

Key Points: 
  • Dominari Financial was formed with the intention of acquiring revenue generating assets in the fintech and financial services industry.
  • This transformative purchase not only accelerates our timetable, but also gives us the organizational infrastructure and technology needed to scale Dominari into a financial services powerhouse," said Carlos Aldavero, President of Dominari.
  • "The board fully supports the diversification strategy of which Dominari Financial is the centerpiece," added Wool.
  • "Once approved by FINRA, this acquisition will catapult Dominari forward and lays the groundwork for future acquisitions.